EIKON THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TELURIDE-008, A REGISTRATIONAL PHASE 2/3 TRIAL OF EIK1001 IN NON-SMALL CELL LUNG CANCER

Reuters · 2d ago

Please log in to view news